All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

AML Hub

AML Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

MPN Hub

MPN Hub

Multiple Myeloma

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact

DONATE

SubtypesTherapeuticsCongressesTrialsExpert OpinionsDRUG UPDATES
2020-06-02T16:19:58.000Z

Alexander study: CD19/22 dual targeting CAR T-cell therapy with pembrolizumab in R/R DLBCL

By Amalia Zachariadis, Sumayya Khan
Featured
Wendy Osborne
Jun 2, 2020
Share:

Bookmark this article

During the American Society of Clinical Oncology (ASCO) Annual Meeting, the Lymphoma Hub was delighted to speak to Wendy Osborne, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK.

In this video, Wendy Osborne discusses the Alexander study: CD19/22 dual targeting CAR T-cell therapy with pembrolizumab in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). She talks about the results from the phase I/II study that assesses the safety and efficacy of this bicistronic approach, which was designed to overcome CD19 escape and CAR T exhaustion.

Alexander study: CD19/22 dual targeting CAR T-cell therapy with pembrolizumab in R/R DLBCL

More about...
Aggressive B-cell lymphomasALEXANDERASCO 2020CAR therapyDiffuse large B-cell lymphomaPembrolizumab

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Related articles

Add bookmark

Lymphoma Hub Satellite Symposium 2019 | DLBCL - chemotherapy-free regimens - Professor Ulrich Jäger

Professor Ulrich Jäger, Medical University of Vienna, Vienna, AT, summarized that the status of DLBCL treatments, with chemotherapy still firmly the...

Jul 30, 2019
Add bookmark

Lymphoma Hub Satellite Symposium 2019 | DLBCL - chemotherapy-free regimens - Professor Ulrich Jäger

Professor Ulrich Jäger, Medical University of Vienna, Vienna, AT, summarized that the status of...

Jul 30, 2019
Add bookmark

Loretta Nastoupil | ASCO 2018 | Overview of checkpoint inhibitors in Lymphoma

Loretta Nastoupil at ASCO 2018 Overview of checkpoint inhibitors in Lymphoma

Jun 4, 2018
Add bookmark

Loretta Nastoupil | ASCO 2018 | Overview of checkpoint inhibitors in Lymphoma

Loretta Nastoupil at ASCO 2018 Overview of checkpoint inhibitors in Lymphoma

Jun 4, 2018

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox